IMNM - Immunome Inc logo

IMNM

Immunome Inc

Rev —top 1%5Y
Hold

Immunome, Inc. develops antibody-drug conjugates and oncology therapeutics, focusing on products like Varegacestat for desmoid tumors and various preclinical ADC candidates. It operates primarily in the healthcare sector, targeting cancer treatment.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $1,967today

Score Overview

1 Year
Score
Net Growth-5.74%
Net TrendShrank
Net Income Consistency
Rev Growth-42.16%
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth-7x
Net Trend20%
Net Income Consistency
Rev Growth
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth-11x
Net Trend17%
Net Income Consistency
Rev Growth
Rev Trend33%
Revenue Consistency

See the full market ranking →

Immunome Inc fundamental performance

Across Immunome Inc's full reported history, from 2020 to 2025, revenue grew from $ 0.00 to $ 6M and net income went from -$ 17M to -$ 212M. Revenue increased in 33% of the years measured; net income in 17%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 27.99
1 Year2025-08-12
$ 9.91182.44%
5 Years2021-08-12
$ 14.2396.70%
All Time2020-10-02
$ 13.45108.10%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 4M-$ 224M$ 582M
2025$ 6M-$ 212M$ 653M
2024$ 9M-$ 292M$ 217M
2023$ 14M-$ 106M$ 138M
2022$ 6M-$ 36M$ 20M
2021$ 0.00-$ 24M$ 49M
IPO2020$ 0.00-$ 17M$ 39M

Explore beyond IMNM

You're looking at Immunome Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies